Clinical Trial Update: Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL [Phase 1]

View source ↗

Summary

Phase 1 trial of JBH492 as monotherapy in chronic lymphocytic leukemia and non-Hodgkin lymphoma reports safety and preliminary efficacy; the study was terminate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• JBH492

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Status: TERMINATED